my new report

Introduction

The decision of the Supreme Court in Novartis AG v. Union of India is often seen as one of the more important judgments in Indian patent law, kinda generally speaking. This case was about how Section 3(d) of the Patents Act, 1970 should be understood, and also about when pharmaceutical inventions can be patented. It came out of Novartis AG’s request for patent protection for the beta crystalline form of Imatinib Mesylate, which is a medication used in cancer treatment. The judgment matters because it basically clarified what “ enhanced therapeutic efficacy ” means within Section 3(d), and it also touched the ongoing worries about patent evergreening in the pharma industry. With this ruling, the Supreme Court set out key yardsticks and guidelines on the patentability of new forms of already-known substances and the kinds of proof that are expected if someone wants patent protection in India. In this article, I will go through the case background, the questions before the Court, what the Court ultimately held, and the main principles it laid down in the Novartis matter, and then look at how that decision has influenced Indian patent jurisprudence.

1. Facts of the Case

• Novartis AG , a Swiss pharmaceutical firm, had this drug called Imatinib Mesylate. Now the thing is, the base compound Imatinib was already known, and in 1993 it was patented in some countries too. Then India, in 2005, amended its patent law so it could match the TRIPS Agreement, basically letting product patents for pharmaceuticals go through. After that, Novartis submitted an application in India, not for the whole compound in general, but specifically for the beta crystalline form of Imatinib Mesylate. But the Indian Patent Office rejected it under Section 3(d) of the Patents Act, 1970. They said, sort of, that this was just a new form of a known substance, and also that it had not shown any stronger “therapeutic efficacy”, or any improved medicinal effect, whatever phrasing you want. So Novartis fought back, first by challenging the refusal before the Madras High Court, then also questioning whether Section 3(d) itself was constitutionally valid. Later on, the matter was appealed up to the Supreme Court of India. And eventually the whole dispute landed at the Supreme Court.

2. Issues Before the Supreme Court

 1: Whether the beta crystalline form of Imatinib Mesylate qualifies as an “invention” under Section 2(1)(j) of the Patents Act.

2:Whether the claimed invention is hit by Section 3(d) of the Patents Act, 1970.

Section 3(d) states that:

A new form of a known substance is not patentable unless it results in enhancement of known efficacy.

So, the core legal question was:

 Does the beta crystalline form of Imatinib Mesylate show “enhanced therapeutic efficacy” over the known substance?

3.What is the meaning of the term “efficacy” under Section 3(d)?

---

Findings from Supreme court Judgement

Patents Claim for patent for beta crystalline form of Imatinib Mesylate-The

beta form gave some beneficial properties like more beneficial flow properties,

better thermodynamic stability and lower hygroscopicity than alpha form-

Novartis made application for EMR (Exclusive Marketing Rights) on March 27,

2002 and was granted in Nov 10, 2003-Five pre-grant oppositions filed before

the application was taken up for prosecution-Patent rejected on four grounds:

anticipation, non-obviousness, not an invention under section 3(d) and

wrongful priority-IPAB dismissed the appeal on June 26, 2009 and reversed

all the findings of the Controller except the one on section 3(d) Novartis did

not appeal to the Supreme Court for the writ petitions challenging the

constitutional vires of section 3(d)Only the appeal over the substantive merit

of the case from the IPAB was continued Held, any attempt to challenge

the IPAB order directly before the Supreme Court side-stepping the High Court needs to be strongly discouraged and this case cannot be treated as a precedent (para 22) Distinction between “invention” and “patentability” as two distinctly separate concepts (para 91) Appellant argued that section 3(d) is not meant to be an exception to clauses (j) and (ja) of section 2(1)-It has no application to the case of the subject product-The product having been classified the test of invention under section 2(1)(j) and (ja) cannot be denied patent for failing to satisfy section 3(d) Held, there is no force in the submission that section 3(d) is a provision ex majore cautela-This submission misses the vital distinction between the concepts of invention and patentability (para 102)-Section 3(d) sets up a second tier of qualifying standards for chemical and pharmaceutical substances in order to leave the door open for true